Business
VolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the second quarter ended June 30, 2025. Volition management will host a conference call tomorrow, August 15 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below.
About this update from Volitionrx Limited
[{"type":"text","content":"Conference call to discuss financial and operational results scheduled for Friday, August 15 at 8:30 a.m. U.S. Eastern Time","length":123,"tagName":"p","attribs":{}},{"type":"text","content":"HENDERSON, Nev., Aug. 14, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the second quarter ended June 30, 2025. Volition management will host a conference call tomorrow, August 15 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below.","length":418,"tagName":"p"},{"id":"2z0r8qSzqLM","subtype":"videoIframe","type":"youtube","url":"https://www.youtube.com/embed/2z0r8qSzqLM","width":560,"height":315,"anchorId":"f70a72e4-eb30-5ffe-93f1-f6818ccc9830"},{"type":"text","content":"Cameron Reynolds, President and Group Chief Executive Officer, said:","length":68,"tagName":"p"},{"type":"text","content":""2025 is a pivotal year for Volition as we focus on commercializing our ground breaking Nu.Q® platform in the human diagnostics market and as reported previously we are in confidential discussions with more than ten companies.","length":231,"tagName":"p"},{"type":"text","content":""We are at various stages of the process across our different pillars ranging from due diligence, to tech transfer, to evaluation of clinical samples, to term sheet negotiation, and contract finalization. I am delighted to see things moving through the funnel, albeit confidentially at this stage, and expect to be able to sign our first agreement in the human diagnostics space this quarter.","length":397,"tagName":"p"},{"type":"text","content":""We believe that our strong clinical evidence supports the broad applicability of our Nu.Q® technology in critical areas such as cancer and sepsis, including as a biomarker of interest to epigenetic drug development, an ever expanding area of focus for big pharma. ","length":270,"tagName":"p"},{"type":"text","content":""Our goal is to secure multiple licensing agreements in the human diagnostics space this year, mirroring our successful strategy in the veterinary market. Similar to the veterinary market, we anticipate diverse deal structures, with potential for up front and milestone payments, and future recurring revenue.","length...